Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$25.13+0.92 (+3.80%)
Close on Nov 18, 2026Market cap $691.46MP/E –Yield –
Fulgent Genetics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Fulgent Genetics's operating income for the twelve months ending Jun 30, 2026 was -$122.28M. For fiscal 2025 it was -$91.10M. The highest annual figure on record is $675.95M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$91.10M | – |
| FY2024 | Dec 31, 2024 | -$73.92M | – |
| FY2023 | Dec 31, 2023 | -$195.53M | -209.5% |
| FY2022 | Dec 31, 2022 | $178.53M | -73.6% |
| FY2021 | Dec 31, 2021 | $675.95M | +133.0% |
| FY2020 | Dec 31, 2020 | $290.16M | – |
| FY2019 | Dec 31, 2019 | -$428.00K | – |
| FY2018 | Dec 31, 2018 | -$5.07M | – |
| FY2017 | Dec 31, 2017 | -$3.48M | -479.3% |
| FY2016 | Dec 31, 2016 | $918.00K | – |
| FY2015 | Dec 31, 2015 | -$5.01M | – |
| FY2014 | Dec 31, 2014 | -$990.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$36.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$34.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$36.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.14M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.08M | -8080.8% |
| Q2 FY2024 | Jun 30, 2024 | -$18.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$151.12M | – |
| Q3 FY2023 | Sep 30, 2023 | $214.00K | -39.2% |
| Q2 FY2023 | Jun 30, 2023 | -$19.80M | -254.7% |
| Q1 FY2023 | Mar 31, 2023 | -$24.82M | -112.3% |
| Q4 FY2022 | Dec 31, 2022 | -$36.55M | -124.2% |
| Q3 FY2022 | Sep 30, 2022 | $352.00K | -99.8% |
| Q2 FY2022 | Jun 30, 2022 | $12.79M | -87.1% |
| Q1 FY2022 | Mar 31, 2022 | $201.93M | -24.3% |
| Q4 FY2021 | Dec 31, 2021 | $150.86M | -33.2% |
| Q3 FY2021 | Sep 30, 2021 | $159.27M | +150.7% |
| Q2 FY2021 | Jun 30, 2021 | $98.90M | +3646.1% |
| Q1 FY2021 | Mar 31, 2021 | $266.92M | – |
| Q4 FY2020 | Dec 31, 2020 | $225.91M | – |
| Q3 FY2020 | Sep 30, 2020 | $63.52M | +4109.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.64M | +794.9% |
| Q1 FY2020 | Mar 31, 2020 | -$1.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$409.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $1.51M | – |
| Q2 FY2019 | Jun 30, 2019 | $295.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$846.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.19M | -1101.8% |
| Q4 FY2017 | Dec 31, 2017 | -$2.07M | -264.4% |
| Q3 FY2017 | Sep 30, 2017 | -$1.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$150.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $219.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.26M | – |
| Q3 FY2016 | Sep 30, 2016 | -$695.00K | – |
See a number that looks wrong?